Search
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigational[L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist.
Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalIt was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences. … [L34324] On July 28, 2023, the EMA also approved Piflufolastat F18 under the brand name PYLCLARI for primary staging or localizing recurrence of prostate cancer.[L47586]
Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15704ApprovedInvestigationalUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.
Mixtures: Vaxigrip Tetra, Suspension for Injection in Pre-filled Syringe, FLUAD Injektionssuspension in einer FertigspritzeAvapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigational[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers.[A189327] Avapritinib shares a similar mechanism with [ripretinib]. … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal
Categories: Bile Salt Export Pump Inhibitors, MATE 2-K InhibitorsMenthyl salicylate
go.drugbank.com/drugs/DB11201ApprovedMenthyl salicylate is an ester of menthol and salicylic acid [L2808]. This product is used to treat minor aches and pains of the muscles/joints (e.g., arthritis, backache, sprains) [L2810].
Mixtures: Rx ActCategories: Anti-Inflammatory Agents, Non-SteroidalSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalOn January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). … For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs.
Cinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedA local anesthetic of the amide type now generally used for surface anesthesia. … It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
Synonyms: 2-N-butoxy-N-(2-diethylaminoethyl)cinchoninamide, 2-butoxy-N-(2-(diethylamino)ethyl)cinchoninamideMixtures: Scheriproct - SalbeChlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnChlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33).
Categories: Drugs Used in DiabetesSynonyms: N-(4-chlorophenylsulfonyl)-N'-propylurea, N-(p-chlorobenzenesulfonyl)-N'-propylureaPrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Categories: Drugs for ConstipationIomeprol
go.drugbank.com/drugs/DB11705ApprovedInvestigationalIomeprol is a tri-iodinated, non-ionic radiographic contrast agent for intraarterial or intravenous use. … [A265090,A265095] Iomeprol first appeared in the market in 1994 [A265095] and is currently used in various diagnostic processes involving x-ray imaging and computed tomography (CT) scans.[L52260]
Synonyms: N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO-5-(N-METHYLGLYCOLAMIDO)ISOPHTHALAMIDE, 1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-((HYDROXYACETYL)METHYLAMINO)-2,4,6-TRIIODO-Categories: Compounds used in a research, industrial, or household setting, X-Ray Contrast Media, Iodinated